Oncolytics Biotech Inc.

NASDAQ:ONCY

Biotechnology

Healthcare
$0.50 +3.03%

+$0.03 today

Market cap
$50.41M
Beta
1.08
P/E (TTM)
-4.3
EPS (TTM)
-$0.32
52W Low $0.56High $1.51

Volume 0.38M

Average 1.26M

Returns on capital

Oncolytics Biotech Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

757.0%

avg 3773.9%

ROIC

-1716.0%

avg -269.1%

ROA

-379.3%

avg -120.0%

Analysis

ROE is currently the strongest return metric at 757.0% versus its period average of 3773.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Thomas C. Heineman

Chief Medical OfficerCAD 675.47K67——

Jared Kelly

Chief Executive Officer & DirectorCAD 582.15K40114.05K0.11%

Kirk J. Look

Chief Financial OfficerCAD 575.18K54——

Allison Hagerman

Chief Technology OfficerCAD 343.8K42115.06K0.11%

John Mark Lievonen

ConsultantCAD 18.26K———

Yujun Wu

VP & Head of Biostatistics————

Jon Patton

Director of Investor Relations & Communication————

Andrew Aromando

Chief Business Officer—5655.10K0.05%

John McAdory

Chief Operating Officer—49——

Compensation is shown in the reported currency; data updated Oct 3, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 12, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

14

$362,615.06

Sells

0

$0.00

Net Transaction Value

+$362,615.06

Net buying

Most Active

Kelly Jared

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Mar 12, 26

Kelly Jared

Direct

Buy$4.8K
Mar 11, 26

Parsons James T.

Direct

Buy$10.3K
Feb 12, 26

Look Kirk

Direct

Buy$10.1K
Feb 12, 26

Andrews Patricia S

Direct

Buy$30.3K
Feb 12, 26

Kelly Jared

Direct

Buy$24.8K
Feb 12, 26

Heineman Thomas Charles

Direct

Buy$10K
Feb 12, 26

Brown Deborah Margaret

Direct

Buy$21.2K
Feb 12, 26

Hagerman Allison

Direct

Buy$8.3K
Feb 12, 26

Seizinger Bernd R.

Direct

Buy$33.9K
Feb 12, 26

Pisano Wayne

Direct

Buy$25.3K

1–10 of 14

Summary

Insiders reported 14 buys worth $362,615.06 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $362,615.06. Kelly Jared was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Oncolytics Biotech Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ONCY's management, answered from reported figures.

Who manages ONCY?

Oncolytics Biotech Inc. (ONCY) lists 9 active executives. The top listed executive is Kirk J. Look, Chief Financial Officer.

Are ONCY insiders buying or selling?

Recent insider activity shows net buying of $362,615.06.